Jason Robins was named Chief Financial Officer of Ocular Therapeutix, Inc. As of November 10, 2026, Ocular Therapeutix, Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 12, 2026 to November 9, 2026, naming 2 appointments and 1 departure (Form 8-K, June 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ocular Therapeutix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Riad Sherif · Role: Director · 8-K, 2026-11-09
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-16
- · In / out: In · Person: Jason Robins · Role: Chief Financial Officer · 8-K, 2026-06-12
Ocular Therapeutix, Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-12 to 2026-11-09. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Ocular Therapeutix, Inc files it.
Also on the record for Ocular Therapeutix, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 9.53% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 3.2% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.13% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 4.31% of the class | 5%+ stakes | Source |
| December 8, 2025 | Stake report, Schedule 13G, by SUMMER ROAD LLC | 5.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.18% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 7.3% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 5.8% of the class | 5%+ stakes | Source |
| July 8, 2025 | Stake report, Schedule 13G, by FMR LLC | 12.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ocular Therapeutix, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Ocular Therapeutix, Inc and the records around it.
Ocular Therapeutix, Inc elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Ocular Therapeutix, Inc
Get an email when Ocular Therapeutix, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ocular Therapeutix, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ocular Therapeutix, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ocular Therapeutix, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | In | Director | 8-K, 2026-11-09 | ||
| 2026-11-09 | Out | 2026-12-31 | 8-K, 2026-11-09 | ||
| 2026-10-16 | Reported | not named in the filing | 8-K, 2026-10-16 | ||
| 2026-06-12 | In | Chief Financial Officer | 8-K, 2026-06-12 |
Who leads Ocular Therapeutix, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Riad Sherif, appointed (filed 2026-11-09).
- Chief Financial Officer: Jason Robins, appointed (filed 2026-06-12).
New leaders reset buying decisions — get the Full Report on Ocular Therapeutix, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Ocular Therapeutix, Inc, with the record behind each one.
Find candidates like Director at Ocular Therapeutix, IncEvery change, in the filing's words
Appointed: Riad Sherif, Director
Election of Riad Sherif, M.D. On November 6, 2026, the Board of Directors (the "Board") of Ocular Therapeutix, Inc. (the "Company"), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately.
Departing: Seung Suh Hong, effective 2026-12-31
Resignation of Seung Suh Hong, Ph.D. On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026.
- Dr. Sherif was designated as a Class I member of the Board to serve until the Company's 2027 annual meeting of stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- Dr. Sherif, age 58, has served as the Chief Executive Officer and a member of the board of directors of Oculis Holding AG, a clinical-stage biopharmaceutical company, since December 2017.
- From June 2016 to September 2017, Dr. Sherif served as Entrepreneur in Residence at the Novartis Venture Fund.
- Previously, Dr. Sherif served as the Region President, Europe, Middle East and Africa, of Alcon, then the eye care division of Novartis AG, from March 2014 to May 2016.
- From January 2002 to March 2014, Dr. Sherif held roles of increasing responsibility at Novartis AG, including as Head of Global Sales for Transplant and Immunology; as Vice President, Latin America Region for Infectious Diseases, Transplant and Immunology; as Vice President, Latin America Region for Novartis Vaccines and Diagnostics, during which time he co-founded Sinergium Biotech, a private vaccine manufacturing joint venture; and most recently as Country President of Novartis Canada and Head of its Canadian pharmaceuticals business.
Reported
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the "Company"), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.
Appointed: Jason Robins, Chief Financial Officer
On June 10, 2026, the Board appointed Jason Robins, the Company's interim Chief Financial Officer, to serve as the Chief Financial Officer.
- Amendment to 2021 Stock Incentive Plan On June 10, 2026, Ocular Therapeutix, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").
- At the 2026 Annual Meeting, the Company's stockholders approved an amendment ("Amendment No. 5") to the Company's 2021 Stock Incentive Plan, as amended (the "2021 Stock Incentive Plan").
- Amendment No. 5, which had previously been adopted by the Company's Board of Directors (the "Board") subject to stockholder approval, increased the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 10,000,000 shares.
- Mr. Robins is continuing to serve as the Company's principal financial officer and principal accounting officer.
- In connection with Mr. Robins' appointment, his annual base salary is increased to $535,100 beginning July 1, 2026, and his annual cash bonus, determined by and payable at the sole discretion of the Board, is targeted at 45% of his annual base salary.
Tools for this story
Each opens in a new tab, filled in for Ocular Therapeutix, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.